March 6, 2023Open Access
View Full PaperPhase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
Key Points
Key points are not available for this paper at this time.
Abstract
MK-0616 demonstrated statistically significant and robust, dose-dependent placebo-adjusted reductions in LDL-C at Week 8 of up to 60.9% from baseline and was well tolerated during 8 weeks of treatment and an additional 8 weeks of follow-up. (A Study of the Efficacy and Safety of MK-0616 Oral PCSK9 Inhibitor in Adults With Hypercholesterolemia MK-0616-008; NCT05261126).